24 Aug 2005 - Response Biomedical Corp. announced that it has met a key development milestone as part of the co-development agreement with 3M Health Care announced on November 29, 2004. Under the agreement, 3M Health Care is funding the development of a new rapid, point-of-care microbiology test in the area of infection prevention based on Response Biomedical's RAMP technology. This collaboration is aimed at introducing a product portfolio to improve the outcome of patients entering the hospital system.
"Hospital acquired infections are a tremendous burden on the health care system costing almost US$10 billion per year in the US alone, and result in approximately 12,000 deaths annually," stated Bill Radvak, President & CEO.
 |
www.bionity.com/news/e/48472 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/48472 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |